On April 5, 2024, the Board of Directors of Astria Therapeutics, Inc. increased the size of the Board from eight to nine directors and elected Sunil Agarwal, M.D., as a director, in each case effective as of April 8, 2024. Dr. Agarwal will serve as a Class III director with a term expiring at the Company?s 2024 annual meeting of stockholders and until such time as his successor is duly elected and qualified, or until his earlier death, resignation or removal. Dr. Agarwal will serve as a member of the Science and Technology Committee of the Board.

Dr. Agarwal has more than 20 years of biotechnology research, development, and commercialization experience. Dr. Agarwal currently serves on the Board of Directors of Arvinas and was previously a Board member of Calithera Biosciences, MyoKardia, and Vitrisa Therapeutics. Throughout his career, Dr. Agarwal has served in leadership and executive roles in the biopharmaceutical industry.

He most recently served as Executive Vice President and Chief Development Officer for Sana Biotechnology and, prior to that, as President of Research and Development at Juno Therapeutics until its acquisition by Celgene. At Ultragenyx he served as Executive Vice President and Chief Medical Officer and at Genentech as Senior Vice President and Global Development Head. He has led global approvals across multiple indications for Rituxan, Actemra, Xolair, Lucentis, Ocrevus, Mepsevii, Breyanzi, and Gliadel.

Dr. Agarwal holds a B.S. in neurobiology from Cornell University and earned his M.D. from Tufts University School of Medicine. He completed his residency at Children?s National Medical Center (CNMC), Washington, D.C., and practiced in the CNMC Pediatric Emergency Department.